Spots Global Cancer Trial Database for brca2 gene mutation

Every month we try and update this database with for brca2 gene mutation cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Early Salpingectomy (Tubectomy) With Delayed Oophorectomy in BRCA1/2 Gene Mutation Carriers	NCT02321228	BRCA1 Gene Muta... BRCA2 Gene Muta... Ovarian Cancer	Salpingectomy w... Risk-reducing s...	25 Years - 45 Years	University Medical Center Nijmegen
Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery	NCT03943173	BRCA-Mutated Ov... BRCA1 Gene Muta... BRCA2 Gene Muta... High Grade Fall... High Grade Ovar... Primary Periton... Stage III Fallo... Stage III Ovari... Stage III Prima... Stage IIIA Fall... Stage IIIA Ovar... Stage IIIA Prim... Stage IIIA1 Fal... Stage IIIA1 Ova... Stage IIIA2 Fal... Stage IIIA2 Ova... Stage IIIB Fall... Stage IIIB Ovar... Stage IIIB Prim... Stage IIIC Fall... Stage IIIC Ovar... Stage IIIC Prim... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar... Stage IVA Fallo... Stage IVA Ovari... Stage IVA Prima... Stage IVB Fallo... Stage IVB Ovari... Stage IVB Prima...	Chemotherapy Olaparib Therapeutic Con...	18 Years -	M.D. Anderson Cancer Center
Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes	NCT02286687	Advanced Malign... ATM Gene Mutati... BRCA1 Gene Muta... BRCA2 Gene Muta... Metastatic Mali... PALB2 Gene Muta... Recurrent Malig... Refractory Mali...	Laboratory Biom... Pharmacological... Talazoparib	18 Years -	M.D. Anderson Cancer Center
Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family Members	NCT02194387	Body Mass Index... BRCA1 Gene Muta... BRCA2 Gene Muta... Breast Carcinom... Cancer Survivor Chronic Lymphoc... Fatigue Health Status U... Lynch Syndrome Ovarian Carcino... Overweight	Dietary Interve... Dietary Interve... Internet-Based ... Internet-Based ... Laboratory Biom... Questionnaire A... Telephone-Based... Telephone-Based...	18 Years -	M.D. Anderson Cancer Center
Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency	NCT03442556	ATM Gene Mutati... BRCA1 Gene Muta... BRCA2 Gene Muta... Castration Leve... Castration-Resi... Homologous Reco... Prostate Carcin... PSA Level Great... PSA Progression Stage IV Prosta...	Carboplatin Docetaxel Laboratory Biom... Rucaparib Camsy... Rucaparib	18 Years -	University of Washington
Early Detection of High Grade Ovarian Cancer Using Uterine Lavage EHUD Study and Duplex Sequencing	NCT04823871	Ovarian Epithel... Carcinoma in Si... Ovarian Cancer	Speiser-cathete...	18 Years - 80 Years	Medical University of Vienna
A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients	NCT01905592	Neoplasms, Brea... Carcinoma of Br... Human Epidermal... BRCA1 Gene Muta... BRCA2 Gene Muta... Ovarian Neoplas...	niraparib Physician's cho...	18 Years -	Tesaro, Inc.
Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects	NCT04030559	ATM Gene Mutati... BRCA1 Gene Muta... BRCA2 Gene Muta... BRIP1 Gene Muta... CDK12 Gene Muta... CHEK1 Gene Muta... CHEK2 Gene Muta... DNA Damage Resp... DNA Repair Gene... FANCA Gene Muta... FANCD2 Gene Mut... FANCL Gene Muta... GEN1 Gene Mutat... NBN Gene Mutati... Prostate Carcin... RAD51 Gene Muta... RAD51C Gene Mut...	Niraparib Niraparib Tosyl... Radical Prostat...	18 Years -	University of California, Davis
Cancer Prevention in Women With a BRCA Mutation	NCT02225015	BRCA1 Gene Muta... BRCA2 Gene Muta... Breast Cancer Ovarian Cancer	Follow-up Telep...	35 Years - 70 Years	Women's College Hospital
A Nutritional Intervention to Decrease Breast Density Among Female BRCA (BReast CAncer Susceptibility Gene) Carriers	NCT02197000	BRCA1 Gene Muta... BRCA2 Gene Muta...	DIM-Avail 100mg	18 Years - 70 Years	Rabin Medical Center
Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability	NCT03428802	BRCA1 Gene Muta... BRCA2 Gene Muta... Locally Advance... Metastatic Mali... POLD1 Gene Muta... POLE Gene Mutat... Recurrent Malig... Recurrent Ovari... Stage III Breas... Stage III Ovari... Stage IIIA Brea... Stage IIIA Ovar... Stage IIIB Brea... Stage IIIB Ovar... Stage IIIC Brea... Stage IIIC Ovar... Stage IV Breast... Stage IV Ovaria... Stage IVA Ovari... Stage IVB Ovari...	Laboratory Biom... Pembrolizumab	18 Years -	Rutgers, The State University of New Jersey
Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer	NCT03377556	ATM Gene Mutati... ATR Gene Mutati... BARD1 Gene Muta... BRCA1 Gene Muta... BRCA2 Gene Muta... BRIP1 Gene Muta... CHEK1 Gene Muta... CHEK2 Gene Muta... FANCA Gene Muta... FANCC Gene Muta... FANCD2 Gene Mut... FANCF Gene Muta... FANCM Gene Muta... NBN Gene Mutati... PALB2 Gene Muta... RAD51 Gene Muta... RAD51B Gene Mut... RAD54L Gene Mut... Recurrent Squam... RPA1 Gene Mutat... Stage IV Squamo...	Laboratory Biom... Pharmacological... Talazoparib	-	SWOG Cancer Research Network
Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer	NCT03552471	BRCA1 Gene Muta... BRCA2 Gene Muta... Folate Receptor... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Recurrent Uteri... Recurrent Uteri... Recurrent Uteri... Platinum Resist...	Laboratory Biom... Mirvetuximab So... Pharmacokinetic... Rucaparib Camsy...	18 Years -	Ohio State University Comprehensive Cancer Center
Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes	NCT02286687	Advanced Malign... ATM Gene Mutati... BRCA1 Gene Muta... BRCA2 Gene Muta... Metastatic Mali... PALB2 Gene Muta... Recurrent Malig... Refractory Mali...	Laboratory Biom... Pharmacological... Talazoparib	18 Years -	M.D. Anderson Cancer Center
Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects	NCT04030559	ATM Gene Mutati... BRCA1 Gene Muta... BRCA2 Gene Muta... BRIP1 Gene Muta... CDK12 Gene Muta... CHEK1 Gene Muta... CHEK2 Gene Muta... DNA Damage Resp... DNA Repair Gene... FANCA Gene Muta... FANCD2 Gene Mut... FANCL Gene Muta... GEN1 Gene Mutat... NBN Gene Mutati... Prostate Carcin... RAD51 Gene Muta... RAD51C Gene Mut...	Niraparib Niraparib Tosyl... Radical Prostat...	18 Years -	University of California, Davis
TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention	NCT04294927	BRCA1 Gene Muta... BRCA2 Gene Muta... RAD51C Gene Mut... RAD51D Gene Mut... BRIP1 Gene Muta... Ovarian Cancer	Risk-reducing s... Risk-reducing s...	25 Years - 50 Years	University Medical Center Nijmegen
ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast Cancer	NCT01009788	Breast Cancer Metastatic Brea... BRCA1 Gene Muta... brca2 Gene Muta...	ABT-888 temozolomide	18 Years -	Massachusetts General Hospital
Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery	NCT03943173	BRCA-Mutated Ov... BRCA1 Gene Muta... BRCA2 Gene Muta... High Grade Fall... High Grade Ovar... Primary Periton... Stage III Fallo... Stage III Ovari... Stage III Prima... Stage IIIA Fall... Stage IIIA Ovar... Stage IIIA Prim... Stage IIIA1 Fal... Stage IIIA1 Ova... Stage IIIA2 Fal... Stage IIIA2 Ova... Stage IIIB Fall... Stage IIIB Ovar... Stage IIIB Prim... Stage IIIC Fall... Stage IIIC Ovar... Stage IIIC Prim... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar... Stage IVA Fallo... Stage IVA Ovari... Stage IVA Prima... Stage IVB Fallo... Stage IVB Ovari... Stage IVB Prima...	Chemotherapy Olaparib Therapeutic Con...	18 Years -	M.D. Anderson Cancer Center
Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation	NCT02953457	BRCA1 Gene Muta... BRCA2 Gene Muta... Ovarian Serous ... Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Durvalumab Laboratory Biom... Olaparib Tremelimumab	18 Years -	Roswell Park Cancer Institute
Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer	NCT03552471	BRCA1 Gene Muta... BRCA2 Gene Muta... Folate Receptor... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Recurrent Uteri... Recurrent Uteri... Recurrent Uteri... Platinum Resist...	Laboratory Biom... Mirvetuximab So... Pharmacokinetic... Rucaparib Camsy...	18 Years -	Ohio State University Comprehensive Cancer Center

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: